Projects

Programme

P4-0127 Pharmaceutical biotechnology: Science for health 
Janko Kos
Period: 1.1.2004―31.12.2024
 
P4-0432 Marine and microbial biotechnology
Ana Rotter (B3: Jerica Sabotič)
Period: 1.1.2022 – 31.12.2027
 

Projects

J3-4503 Translational irregularities underlying C9orf72-associated amyotrophic lateral sclerosis and frontotemporal dementia
PI: Boris Rogelj
Period: 1. 10. 2022 – 30.9.2025

J3-4531 On-demand Contact Based Antimicrobial Surfaces: Human and Environmental Safe Infection Control Strategy
PI: Marija Vukomanović (B3: Milica Perišić Nanut)
Period: 1. 10. 2022 – 30.9.2025

J4-4555 Exploring the biofilm phenotype and surfactome of Listeria monocytogenes to predict its persistence and pathogenicity potential using machine learning
PI: Jerica Sabotič
Period: 1. 10. 2022 – 30.9.2025

J7-4420 Selective mechanical removal of bacterial biofilms by conjugated magnetic nanoparticles
PI: Aleš Berlec
Period: 1. 10. 2022 – 30.9.2025

L7-4567 Plasma VUV and UV radiation – a method for successful deactivation of Aflatoxins
PI: Nina Recek (B3: Helena Motaln)
Period: 1. 10. 2022 – 30.9.2025

Z4-4566 Engineering lactic acid bacteria for tumour targeted delivery of anticancer agents
PI: Abida Zahirović
Period: 1. 10. 2022 – 30.9.2024

J7-4637 Antibacterial alloys: development by additive 3D manufacturing, characterization and clinical applications
PI: Ingrid Milošev (B3: Helena Motaln)
Period: 1. 10. 2022 – 30.9.2025

J7-4418 Nanofibers for codelivery of selected microbiota cocktails and antimicrobials for local treatment of vaginal infections
PI: Špela Zupančič (B3: Aleš Berlec)
Period: 1. 10. 2022 – 30.9.2025

J4-4548 Microplastics as a vector of pathogen contamination, infection and resistance: a case of Campylobacter in poultry production and processing
PI: Anja Klančnik (B3: Jerica Sabotič)
Period: 1. 10. 2022 – 30.9.2025

J3-3079 Bactericidal nanoblades: a proof-of-concept approach for bimodal chemo-mechanical eradication of persistent biofilms
PI: Stane Pajk (B3: Jerica Sabotič)
Period: 1.12.2021 – 30.11.2024

J3-3071 Cathepsins B and X in breast cancer stem cells – molecular targets and relevance for antitumor therapy
PI: Ana Mitrović
Period: 1. 10. 2021 – 30.9.2024

J4-3088 Intra-biofilm dynamics of Campylobacter with other bacteria: effects on biofilm formation and composition with a view to the design of innovitive control strategies
PI: Anja Klančnik (B3: Jerica Sabotič)
Period: 1. 10. 2021 – 30.9.2024

J4-3096 Recombinant probiotics as bio-alternative antimicrobial approach against Clostridioides difficile
PI: Borut Štrukelj (B3: Aleš Berlec)
Period: 1.10.2021 – 30.9.2024

Cell4Chem (ERA-Net CoBioTech) Engineering microbial communities for the conversion of lignocellulose into medium-chain carboxylates
PI: Aleš Berlec
Period: 1.7.2021-30.6.2024

N3-0184 (CEUS GA ČR): Small protein blockers of IL-23/IL-17 axis as intestinal inflammation inhibitors secreted by probiotic bacteria.
PI: Aleš Berlec
Period: 1.3.2021 ― 28.2.2024

PID13158 Instruct-ERIC: Bacterial cell wall glycans
PI: Jerica Sabotič
Period: 1.11.2020―31.12.2020

J4-2543 FunContrAPest: Novel Fungal Proteins as Biopesticides for Control of Challenging Invasive Alien Agricultural Pestst
PI: Jerica Sabotič
Period: 1.11.2020―31.10.2023

CA19123 Protection, resilience, rehabilitation of damaged environment
PI: Andrea Pietrelli (B3: Aleš Berlec)
Period: 21.9.2020 ― 10.9.2024

J3-2516 Cystatin F as a mediator of immunosuppression in glioblastoma microenvironment
PI: Milica Perišić Nanut
Period: 1.9.2020―31.8.2023

N3-0141 Nuclear Transport defects in frontotemporal dementia
PI: Boris Rogelj
Period: 1.3.2020―28.2.2023

CA18238 European transdisciplinary networking platform for marine biotechnology
PI: Ana Rotter (B3: Jerica Sabotič)
Period: 1.10.2019 – 30.9.2023

J4-1776 Improvement of immunotherapeutic potential of NK cells through modulation of cystatin F
PI: Janko Kos
Period: 1.7.2019―30.6.2022

J4-1771 New antimicrobial strategies in prevention of biofilm formation by using lectins that inhibit bacterial adhesion
PI: Jerica Sabotič
Period: 1.7.2019―30.6.2022

J3-9263 Pathogenic role of paraspeckle-like nuclear bodies in neurodegenerative diseases ALS and FTD
PI: Boris Rogelj
Period: 1.7.2018―30.6.2021

J3-9267  Inhibition of cathepsin X activity as a novel strategy for the treatment of Parkinson’s disease
PI: Anja Pišlar (B3: Janko Kos)
Period: 1.7.2018―30.6.2021

J4-9299 Targeting Campylobacter adhesion in the fight against antimicrobial resistance
PI: Anja Klančnik (B3: Jerica Sabotič)
Period: 1.7.2018―30.6.2021

J4-9327  Targeting, imaging and treating of colorectal cancer with safe theranostic bacteria
PI: Aleš Berlec
Period: 1.7.2018―30.6.2021

J3-9262 Advanced surface finishing technologies for antibacterial properties of patient specific 3D printed implantable materials
PI: Ita Junkar (B3: Boris Rogelj)
Period: 1.7.2018―30.6.2021

J7-9399 Phase transitions in systems of nucleotide repeat expansions associated with neurodegenerative diseases
PI: Irena Drevenšek Olenik (B3: Boris Rogelj)
Period: 1.7.2018―30.6.2021

L4-9325 Development of new, environment-friendly approaches for plant and human virus inactivation in waters
PI: Maja Ravnikar (B3: Boris Rogelj)
Period: 1.7.2018―30.6.2021

Z3-9273 Use of cathepsin B and X inhibitors for the improvement of antitumor therapy
PI: Ana Mitrović
Period: 1.7.2018―30.6.2020

J3-8201 Nuclear transport defects in neurodegenerative diseases
PI: Boris Rogelj
1.5.2017―30.4.2020

J4-8227 Cathepsin X inhibitors impair the resistence of tumor cells to antiprotease therapy 
PI: Janko Kos
Period: 1.5.2017 – 30.04.2020

Z3-7307 Vloga celičnega lipidnega metabolizma pri amiotrofični lateralni sklerozi in frontotemporalni lobarni degeneraciji (Slovene)
PI: Anja Pucer Janež
Period: 1.2.2017―31.12.2019

J7-7424 Evaluation of possible harmful effects of nanoparticles and underlying mechanisms ? from physico-chemical and in vitro toxicity characterisation to innate immune system activation
PI: Vladimir B. Bregar (B3: Boris Rogelj)
Period: 1.1.2016―31.12.2018

J3-6785 Genetics and pharmacogenomics of inflammatory bowel diseases and genetically related chronic immune diseases
PI: Uroš Potočnik (B3: Boris Rogelj)
Period: 1.7.2014―30.6.2017

Z3-6802 Molecular mechanisms of skeletal muscle atrophy: Implications in age, muscle disease and space habitation.
PI: Anja Kovanda
Period: 1.11.2014―30.6.2017

J3-6789 Pathogenic mechanism of the C9orf72 expanded hexanucleotide repeat mutation in neurodegeneration
PI: Boris Rogelj
Period: 1.7.2014―30.6.2017

J4-6811 The role of cysteine protease inhibitors in NK cell mediated lysis of tumour cells
PI: Janko Kos
Period: 1.7.2014―30.6.2017

J3-5502 Dysregulation of TDP-43 expression in amyotrophic lateral sclerosis and frontotemporal lobar degeneration
PI: Boris Rogelj
Period: 1.8.2013―31.7.2016

J4-5529 Nitroxoline and its derivatives as new antitumour drugs
PI: Kos Janko
Period: 1.8.2013―31.7.2016

J7-5460 Post-transcriptional regulatory networks in neurodegenerative diseases.
PI: Jernej Ule (B3: Boris Rogelj)
Period: 1.8.2013―31.7.2016

J1-5450 Protein engineering of recombinant probiotic lactic acid bacteria for treatment of irritative bowel disease
PI: Borut Štrukelj
Period: 1.8.2013―31.7.2016